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A B S T R A C T
Background
Gout is one of the most frequently occurring rheumatic diseases, worldwide. Given the well-known drawbacks of the regular treatments
for acute gout (non-steroidal anti-inflammatory drugs (NSAIDs), colchicine), systemic corticosteroids might be safe alternatives.
Objectives
To assess the efficacy and safety of systemic corticosteroids in the treatment of acute gout in comparison with placebo, NSAIDs,
colchicine, other active drugs, other therapies, or no therapy.
Search methods
Searches were done in the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane
Library 2007); MEDLINE (1966 to 2007) through PubMed; EMBASE (1974 to 2007); Web of Science (1975 to 2007); LILACS
(1986 to 2007); and databases of ongoing trials (up to April 2007).
Selection criteria
Randomized controlled trials and controlled clinical trials investigating the use of systemic corticosteroids in the treatment of acute
gout were included.
Data collection and analysis
Two review authors decided independently which trials to include. The same review authors also collected the data in a standardised
form and assessed the methodological quality of the trial using validated criteria. When possible, continuous and dichotomous data
were summarised statistically.
Main results
Three head to head trials involving 148 patients (74 systemic corticosteroids; 74 comparator drugs) were included. Placebo-controlled
trials were not found. In the studies, different kinds of systemic corticosteroids and different kinds of control drugs were used,
both administered in different routes. Intramuscular triamcinolone acetonide was compared respectively to oral indomethacine, and
intramuscular adrenocorticotropic hormone (ACTH); oral prednisolone (together with a single intramuscular diclophenac injection)
was compared to oral indomethacine (together with a single placebo injection). Outcome measurements varied: average number of
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days until total relief of signs, mean decrease of pain per unit of time in mm on a visual analogue scale (VAS) - during rest and activity.
In the triamcinolone-indomethacine trial the clinical joint status was used as an additional outcome. Clinically relevant differences
between the studied systemic corticosteroids and the comparator drugs were not found; important safety problems attributable to the
used corticosteroids were not reported. The quality of the three studies was graded as very low to moderate. Statistical pooling of results
was not possible.
Authors’ conclusions
There is inconclusive evidence for the efficacy and effectiveness of systemic corticosteroids in the treatment of acute gout. Patients with
gout did not report serious adverse effects from systemic corticosteroids, when used short term.
P L A I N L A N G U A G E S U M M A R Y
Systemic corticosteroids for acute gout
This summary of a Cochrane review presents what we know from research about the effect of systemic corticosteroids for acute gout.
The review shows that in people with gout:
- systemic corticosteroids may slightly improve patients’ assessment of pain and disability. However, this could have occurred by chance;
- there is no precise information about side effects and complications. Only a minority of the patients treated with the steroid oral
prednisolone reported minor side effects.
What is gout, and what are systemic corticosteroids?
Gout is a sudden, very painful joint inflammation (arthritis). It usually affects the big toe. The inflammation, which is caused by urate
crystals, leads to swelling and redness of the joint, and makes it painful to move or even to touch.
Systemic corticosteroids are drugs that imitate the corticosteroids that are naturally produced by your own body and may help reduce
swelling, redness and pain in joints. Systemic corticosteroids come in a pill form or as an injection given by your doctor.
B A C K G R O U N D
Gout is a frequently occurring form of arthritis, mostly localized
in the first metatarsophalangeal joint, with the tendency to re-
cur easily. It is an extremely painful acute inflammatory arthri-
tis with a sudden and dramatic onset, often beginning at night
(Schumacher 1996; Schlesinger 2004). The arthritis wanes over
days to weeks, with or without treatment (Bellamy 1987; Arnold
1988). The severe and painful inflammation is caused by the depo-
sition of monosodium urate (MSU) crystals in the affected joint.
The identification of these MSU crystals in the synovial fluid af-
ter joint aspiration and microscopic investigation comprises the
gold standard for diagnosis. It is thought that the MSU crystal
deposition in the joint is a consequence of high serum urate levels,
caused by metabolic overproduction or renal undersecretion, or
both (Bieber 2004). Uric acid is an end product of purine nu-
cleotide catabolism and is excreted largely by the kidneys. Gout
affects at least 1% of adult men in their lifetime, inWestern coun-
tries (Terkeltaub 2003; Bieber 2004). The estimated incidence of
gout in these countries is 0.6 to 2.1 per 1000 per year (Arromdee
2002; Van de Lisdonk 2003; Schlesinger 2004; Van der Linden
2004), with a prevalence of 3 to 7.5 per 1000 per year (Van de
Lisdonk 2003; Schlesinger 2004; Van der Linden 2004).
In current practice, non-steroidal anti-inflammatory drugs
(NSAIDs) and colchicine are the most commonly used agents
for the treatment of acute gout (Kim 2003; Terkeltaub 2003;
Schlesinger 2004).
In the past decades several studies have shown effectiveness of
NSAIDs in patients with acute gouty arthritis in reducing pain,
swelling, disability, redness and temperature (Sturge 1977; Altman
1988; Maccagno 1991; Shrestha 1995; Schumacher 2002; Rubin
2004; Sutaria 2006). Despite the fact that a recent systematic re-
view located only one placebo-controlled NSAID study, NSAIDs
are widely accepted as the drugs of first choice (Sutaria 2006).
Gastrointestinal complications like gastritis, ulceration, bleeding,
and perforation are the most frequent adverse effects of NSAIDs.
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These adverse effects can emerge even within a short period of
use (Lewis 2002). Other less frequent side effects of NSAIDs are
allergic symptoms, headache, dizziness, and sleepiness. Further-
more, decreased renal function in patients with chronic gout has
been attributed to the use of NSAIDs (Perez-Ruiz 2000). Finally,
NSAIDs have drawbacks secondary to age and cardiovascular risks,
in particular myocardial infarction, loss of renal function, fluid
retention, and concurrent use of anticoagulants (Lewis 2002; Kim
2003; Schlesinger 2004; Kearney 2006, Sutaria 2006, Underwood
2006). These drawbacks can be expected in gout patients as they
are generally older and often have pre-existing co-morbidities, like
renal and cardiovascular disease (Abbott 1988; Conaghan 1994;
Fam 1998; Janssens 2003; Bieber 2004; Janssens 2006; Krishnan
2006).
Colchicine has a longstanding history in the treatment of acute
gout, even before NSAIDs were available. It is considered a first al-
ternative whenNSAIDs are contraindicated. It has a narrow thera-
peutic window with hazardous side effects, even when patients are
treated according to accepted guidelines (Morris 2003). The evi-
dence for its therapeutic use in acute gout is based on one placebo-
controlled trial (Ahern 1987). This was the conclusion of a recent
Cochrane systematic review (Schlesinger 2006). High doses are
advised until relief of pain is obtained, or vomiting or diarrhoea
occurs (Conaghan 1994; Morris 2003). The plasma half-life of
colchicine is longer when renal function is impaired, a condition
which is often seen in gout patients (Wise 1996; Petersel 2007).
Other infrequent but serious side effects are bone marrow sup-
pression, myopathy, and neuropathy (Conaghan 1994).
There are arguments to re-appraise the routine status of NSAIDs
and colchicine in the treatment of acute gout because of their
contraindications and adverse effects (Sutaria 2006). Alternatives
with a better risk benefit profile are needed because it can be
expected that many gout patients are at risk on routine treat-
ment withNSAIDs and colchicine. Corticosteroids are oftenmen-
tioned to be such an alternative, particularly in elderly people, as
they have potentially effective anti-inflammatory capacity andmay
have fewer adverse effects when used short term (Groff 1990; Fam
1998; Rowe 2001; Kim 2003; Terkeltaub 2003; Schlesinger 2004;
Gotzsche 2005; Sutaria 2006; Underwood 2006). We were aware
of a few studies investigating short-term treatments of gout with
systemic corticosteroids, which demonstrated treatment effects
(Groff 1990, Alloway 1993, Siegel 1994,Werlen 1996). However,
these studies had only small numbers of patients, they investi-
gated different types of corticosteroids, and showed considerable
methodological differences. We were not able to find systematic
reviews on this topic, systemic corticosteroids for acute gout. The
reviews that we did find were predominantly narrative, without
a predefined systematic method, or without a focus on corticos-
teroids (Groff 1990; Schumacher 1996; Wise 1996; Terkeltaub
2003; Schlesinger 2004; Sutaria 2006).
O B J E C T I V E S
To assess the efficacy and safety of systemic corticosteroids in the
treatment of acute gout in comparison with placebo, NSAIDs,
colchicine, other active drugs, other therapies, or no therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials and controlled clinical trials investi-
gating the use of systemic corticosteroids in the treatment of acute
gout were eligible for inclusion.
Types of participants
Patients of any age with an acute gouty arthritis diagnosed after
identification of MSU crystals were considered for this review.
Because of the expected limited number of trials adhering to this
criterion, we also considered trials involving patients with a gout
diagnosis according to the preliminary criteria of the American
College of Rheumatology, the ACR criteria (Wallace 1977), or
based on other clinical grounds.
Types of interventions
Only studies that evaluated the benefit or safety of a mono-ther-
apy with systemic corticosteroids were eligible for inclusion. We
searched for all studies that compared this therapy with placebo,
NSAIDs, colchicine, other active drugs, other therapies, or no
therapy.
Types of outcome measures
Primary outcomes were based on patients’ assessment of pain and
disability, investigators’ assessment of clinical symptoms (swelling,
erythema, tenderness), and adverse events. If eligible, secondary
outcomes such as cost-effectiveness were also considered.
Search methods for identification of studies
See: Cochrane Musculoskeletal Group methods used in reviews.
Searching was performed as outlined in the Cochrane Handbook
for Systematic Reviews of Interventions. The following electronic
databases were used for the identification of the trials.
* The Cochrane Library, including the Cochrane Central Register
of Controlled Trials (CENTRAL) (up to 2007).
* PubMed (including MEDLINE) (1966 to 2007).
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* EMBASE (1974 to 2007).
* Web of Science (1975 to 2007).
* LILACS (www.bireme.br/bvs/I/ibd.htm) (1986 to 2007).
* Databases of ongoing trials (up to April 2007).
Ongoing trial databases included: Current Controlled Trials (http:
//www.controlled-trials.com, with links to other databases of on-
going trials); UKNational Research Register (http://www.update-
software.com/National/nrr-frame.html); USA Center Watch
Clinical Trials Listing Service (http://www.CenterWatch.com/
); USA National Institutes of Health (http://clinicalstud-
ies.info.nih.gov/).
We performed a search combining search procedures for clinical
trials, gout, and systemic corticosteroids (see below). We com-
bined these procedures with the Boolean operator AND. In the
strategy for clinical trials we used a sensitive and valid procedure
(Robinson 2002); in the search strategy for gout and corticos-
teroids we developed a strategy using keywords (MeSH headings)
and text words. We tested our procedures extensively by running
the searches and subsequently checking whether known articles
on the topic of gout or corticosteroids were missing.
The search strategy for PubMed is given below (see Appendix 1 as
well).
#1 Gout
“gout” [mh] OR gout* [tw] OR “Hyperuricemia”[mh] OR toph*
[tw] OR arthritis uric* [tw] OR artritis uric* [tw] OR uric acid
dis* [tw]
#2 Corticosteroids
“Glucocorticoids”[mh]OR“AdrenalCortexHormones”[mh]OR
“Steroids”[mh] OR glucocortic* [tw] OR adrenal Cortex Horm*
[tw] OR prednison* [tw] OR prednisol* [tw] OR cortison* [tw]
ORhydrocort* [tw]ORmethylprednis* [tw] OR triamcinol* [tw]
OR dexamethas* [tw] OR betamethas* [tw] OR beclomethas*
[tw] OR paramethas* [tw] OR dexametas* [tw] OR betametas*
[tw] OR beclometas* [tw] OR parametas* [tw]
#3 Controlled trials
(Randomized controlled trial [pt] OR controlled clinical trial [pt]
OR randomized controlled trials [mh] OR random allocation
[mh] OR double-blind method [mh] OR single-blind method
[mh] OR clinical trial [pt] OR clinical trials [mh] OR (clinical
trial [tw]) OR ((singl*[tw] OR doubl* [tw] OR trebl* [tw] OR
tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (latin square
[tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR
research design [mh:noexp] OR comparative study [mh] OR eval-
uation studies [mh] OR follow-up studies [mh] OR prospective
studies [mh] OR cross-over studies [mh] OR control* [tw] OR
prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT
human [mh])
Whole search
#1 AND #2 AND #3
Abbreviations: mh: exploded medical subject heading (Medline
medical index term); mh:noexp: non-exploded medical subject
heading (MEDLINE medical index term); tw = text word; pt =
publication type. The asterisk (*) stands for any character(s).
For EMBASE and Current Contents, this strategy was adapted
because these databases have different interfaces. The necessary
changes in the search string were done so that the search became
more sensitive (that is yielded a higher number of ’hits’).
Data collection and analysis
Study selection
To select studies for further assessment, two review authors (HJ
and PL) independently reviewed the titles and abstracts of every
record retrieved. Articles were selected if this information indi-
cated that the study: (1) included patients with crystal-proven gout
or patients with a gout diagnosis based on the preliminary criteria
of the ACR, or with a diagnosis on other clinical grounds; (2)
compared systemic corticosteroid treatment with placebo or other
interventions; (3) assessed one or more of the required outcome
measures; (4) used random allocation [or for controlled clinical
trials, an allocation under the control of the investigator] to the
comparison groups. If there was any doubt regarding the informa-
tion from the title and abstract, the full article was retrieved for
clarification. In a case of disagreement about including a study, a
third review author (EvdL) was consulted for a definitive decision.
Inter-observer agreement for study selection was measured using
the kappa statistic (Cohen 1960).
Quality assessment of the selected studies
Two review authors (HJ and PL) assessed the quality of each re-
trieved trial independently using the following quality character-
istics.
1. Selection bias. A) Method of randomization: the randomiza-
tion procedure was scored as adequate when the resulting se-
quences were unpredictable (i.e., computer generated schemes,
tables of random numbers, coin tossing). B) Allocation conceal-
ment: scored as adequate when participating patients and investi-
gators could not foresee assignment (i.e., by central randomization
remote from trial site, sequentially numbered and sealed radio-
opaque envelopes).
2. Performance bias. Methods of (double) blinding, if applica-
ble: blinding was considered adequate when the interventions
were similar in size, colour, and shape; or when a double dummy
methodwas applied. If trials reported blindingwe also investigated
whether the blinding was checked.
3. Attrition bias. A) Description of withdrawals and drop-outs:
handling of drop-outs was considered adequate when studies gave
a complete description of all patients failing to participate until
the end of the trial and when the data were analysed on an inten-
tion-to-treat (ITT) basis. B) Number of drop-outs: overall drop-
out rate < 15% was considered adequate. C) Selective drop-out:
a difference in drop-out rate between the groups < 10% was con-
sidered adequate.
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4. Detection bias. Method of blinding outcome assessment: this
blinding was considered adequate if the researchers assessing the
outcomes were completely blinded for the intervention.
In a case of disagreement regarding the assessment of the quality
characteristics, one of the other review authors (FvdL) was invited
to make the final decision.
In addition to these criteria, studies were broadly subdivided
into the following three quality scores, as recommended in the
Cochrane Handbook for Systematic reviews of Interventions
(Higgins 2005).
A - All quality criteria met: 1. adequate randomization and alloca-
tion concealment, 2. adequate blinding, 3. adequate ITT analysis
or drop-out rate less than 15% and selective drop-out less than
10%, or both; low risk of bias.
B - One or more quality criteria only partially met: 1. adequate
randomization or adequate allocation concealment, 2.mentioning
of blinding but exact method unclear, 3. inadequate or unclear
ITT analysis but drop-outs less than 15% or selective drop-out
less than 10%); moderate risk of bias.
C - One or more quality criteria not met: 1. inadequate randomi-
sation and allocation concealment, 2. inadequate or no blinding,
3. inadequate ITT and drop-out rate equal to or greater than 15%
and selective drop-out equal to or greater than 10%; high risk of
bias.
Data extraction
Two review authors (HJ and PL) independently extracted the data
concerning characteristics of the selected studies by using a stan-
dard form. This form included the following items.
1. General aspects: title, authors, source, contact address; language
of publication; year of publication; duplicate publication; spon-
soring.
2. Trial characteristics: design and setting; randomization (and
method); allocation concealment (and method); blinding (pa-
tients, people administering treatment, outcome assessors) and
check of successful blinding.
3. Intervention details: placebo or comparison interventions, or
both (dose, route, timing); co-medication or other accompanying
treatment (dose, route, timing).
4. Participant details: sampling (random or convenience); exclu-
sion criteria; total number and numbers in the comparison groups;
age, sex, and other baseline characteristics; diagnostic criteria; only
new or all cases; assessment of compliance; withdrawals and losses
to follow up (reasons, description).
5. Outcome measures and methods of assessing outcomes: con-
tinuous scales (e.g., visual analogue scales); dichotomous out-
comes (e.g., presence or absence of pain); categorical scales (e.g.,
none, mild, moderate, severe, extreme); validated questionnaires;
or other reported methods (e.g., amount of days required for total
resolution of all symptoms); and length of follow up.
Data analysis
We planned to summarize the data statistically, if available and
sufficiently homogeneous.
We expected dichotomous, ordinal, and continuous data. If pos-
sible, dichotomous data were expressed as relative risks (RR).
Peto odds ratio (Peto OR) were used when incidence rates were
small.We expressed continuous data as weightedmean differences
(WMD) when outcomes were measured in a similar way. In all
other cases, standardized mean differences (SMD) were used.
We intended to calculate the overall results based on the random-
effects model; to test the heterogeneity using the Z-score and the
Chi-square statistic (significance level P < 0.10); and to quantify
the effect of heterogeneity bymeans of the I2 statistic, ranging from
0 to 100% including its 95% confidence interval. I2 demonstrates
the percentage of total variation across studies due toheterogeneity,
and it could be used to judge the consistency of the evidence
(Higgins 2002). A value greater than 50% may be considered as
substantial heterogeneity. Possible sources of heterogeneity were
assessed by sensitivity and subgroup analyses. Publication bias was
tested using a funnel plot.
The analyses were performed with the most recent version of
RevMan Analyses in Review Manager.
Sensitivity and subgroup analyses
Wepreplanned sensitivity analyses to evaluate the influence on the
effect size of the following.
1. Published versus unpublished studies, if any.
2. Studies with or without certain quality characteristics: ade-
quate randomization; adequate allocation concealment; adequate
method of blinding; adequate ITT analyses; adequate blinding for
outcome assessment; adequate method of blinding of analyses; an
overall drop-out rate less than 15%; difference of drop-out rates
between the main treatment groups less than 10%; a quality score
A or B, as recommended in the Cochrane Handbook for System-
atic reviews of Interventions (compared to studies with score of
C)(Higgins 2005).
3. Small versus large studies.
4. English language versus other than English language.
5. Sponsored by industry versus other or no industry funding.
6. Gout diagnosis based on identification of MSU crystals versus
no crystal identification.
We also preplanned subgroup analyses to explore the influence on
effect sizes of the following variables.
1. Age.
2. Gender.
3. The route of administration (oral, rectal, intramuscular).
4. Type of steroid.
5. Dose (low, medium, high; based on data).
6. Duration of intervention.
7. Diagnosis criteria (crystal proven, according to ACR, other).
8. Race.
9. Blood level of uric acid.
Finally, for the exploration of the robustness of the results, we
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planned to repeat the analysis using different measures of effect
size (relative risk, risk difference) and different statistical models
(fixed-effect and random-effects models).
Clinical relevance tables
When data were appropriate, we planned to compile clinical rele-
vance tables to improve the readability of the review. For dichoto-
mous outcomes, we planned to calculate the number needed to
treat from the relative risk, using the Visual Rx NNT Calculator
(Cates 2003). For continuous outcomes and when possible, the
absolute benefit as the difference between the improvement in the
intervention group and the improvement in the control group was
assessed in the units as given in the original publication. Moreover,
we intended to calculate the relative difference in improvement as
the difference of the percentage change in the intervention group
and the percentage change in the control group.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We identified 2083 study titles and abstracts from the predefined
databases. Eight of 2083 were independently selected by the two
review authors (HJ and PL) to retrieve the full article with the aim
of evaluating the definite eligibility for inclusion in the review. The
inter-observer agreement of this selection procedure, expressed as
kappa, was 0.93 (95%CI 0.80 to 1.00; standard error 0.067).
After reading the full publication, both authors independently
concluded that four of the eight studies did not meet the in-
clusion criteria (Axelrod 1988; Groff 1990; Conaghan 1994;
Werlen 1996). One study was retrieved from trial registers
(ISRCTN14648181). This study is being conducted by our own
group, and to date the data are not analysed or published. Finally,
we selected three studies for inclusion (Alloway 1993; Siegel 1994;
Man 2007).
In the first included study, intramuscular injections with tri-
amcinolone acetonide were compared with oral indomethacine
(Alloway 1993). In this study the diagnosis of gout in the 27 par-
ticipants (all male) was confirmed by identification of MSU crys-
tals. Afflicted joints were not described. The mean number of in-
volved joints per patient was more than two. Exclusion criteria
were: any infectious process, anticoagulant therapy, uncontrolled
diabetes mellitus. Patients currently taking colchicine, allopurinol,
or an uricosuric agent were allowed to continue this medication
during the study. Triamcinolone acetonide-treated patients were
given paracetamol with codeine for analgesia. Fourteen patients
(mean age 61.2 years) were injected once with 60 mg triamci-
nolone acetonide and, if necessary, an additional injection. Patients
were eligible to receive a second injection if they had less than
50% improvement at the first follow up. Three patients received
a second injection two days after entry in the study. Thirteen pa-
tients (mean age 62.8 years) received indomethacine tablets, 50
mg three times a day, with permission to taper their medication af-
ter at least two days in response to symptomatic improvement. An
important difference between the two treatment groups at base-
line was that five patients in the triamcinolone acetonide group
versus one patient in the indomethacine group used colchicine.
Seven patients were lost to follow up (four in the triamcinolone
acetonide group, three in the indomethacine group). Patients were
evaluated by an unblinded observer at 1 to 2, 3 to 4, 10 to 14,
and 30 days for symptomatic improvement (using a 5-point-scale:
total resolution, improvement of > 50%, improvement of <50%,
no change, worsening of symptoms or involvement of previously
uninvolved joints), for the number of active joints, the presence
of toxicity to therapy, and the presence of rebound arthropathy.
The final efficacy outcomes were the number of days required for
total resolution of all symptoms, and the clinical joint status at 3
follow-up moments.
In the second study, intramuscular injections with triamcinolone
acetonide were compared with intramuscular injections of adreno-
corticotropic hormone (ACTH) (Siegel 1994). All 31 patients (all
male) had their diagnosis of acute gout confirmed by joint aspi-
ration of MSU crystals. Afflicted joints were not described. The
mean number of involved joints was more than 2.5 for each pa-
tient. Patients with a history of uncontrolled diabetes, congestive
heart failure, infection, or severe coronary artery disease were ex-
cluded. Patients currently taking colchicine, allopurinol, or an uri-
cosuric agent were allowed to continue this medication during the
study. Sixteen patients (mean age 62.4 years) were injected with
60 mg triamcinolone acetonide and, if necessary, one or more ad-
ditional injections. Fifteen patients (mean age 69.6 years) were
given 40 IU ACTH intramuscularly and, if necessary, one or more
additional injections. One patient allocated to ACTH treatment
was lost to follow up for unknown reasons. Patients were eligible
for a repeat injection if they had < 50% improvement at each sub-
sequent follow-up visit. Two patients in the ACTH group did not
reach a 50% improvement after three injections and were treated
with triamcinolone acetonide, but were not analysed. The time
interval between re-injections was not reported. There were no sta-
tistical differences between the two treatment groups at baseline,
except for a higher erythrocyte sedimentation rate (ESR) in the tri-
amcinolone acetonide group: 45.57 versus 40.25 (P-value 0.003).
The researchers did not consider this difference clinically relevant.
Patients were evaluated by unblinded (different) observers at 1 to
2, 3 to 4, 10 to 14, and 30 days for symptomatic improvement
(using a 5-point-scale: total resolution, improvement of > 50%,
improvement of <50%, no change, worsening of symptoms or
involvement of previously uninvolved joints), for the number of
active joints, for the clinical joint status, for side effects, and for
rebound arthropathy. The final efficacy outcome was the number
of days to 100% resolution of the symptoms.
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In the third included trial, oral prednisolone was compared to
intramuscular diclophenac combined with oral indomethacine
(Man 2007). Diagnosis of all 90 patients in this study was based
on clinical judgement, without predefined criteria. Afflicted joints
were not described. In more than 90% of the patients a single
joint was involved, most of the time in the lower limb. Exclu-
sion criteria were: clinical suspicion of sepsis or other joint disease;
lack of transport or telephone after diagnosis; significant co-mor-
bidity that would interfere with assessment; dementia or confu-
sion; active gastrointestinal symptoms; serum creatine level greater
than 200 mmol/l; bleeding disorder; allergy to a study drug; joint
aspiration that excluded the diagnosis of gout. Patients were in-
structed to use paracetamol (1 gram every 4 hours) as required.
All patients in the diclophenac plus indomethacine group (N =
46, mean age 66 years) received an intramuscular injection of 75
mg diclophenac at the start of the trial, and 50 mg indomethacine
three times a day for two days then 25 mg indomethacine three
times a day for three days. Patients in the predisolone group (N
= 44, mean age 64 years) received an initial placebo injection and
30 mg prednisolone daily for five days. There were no important
differences between the treatment groups at baseline. The mean
rate of decrease in pain at rest and with activity during the first
two hours and at five-day follow ups were the primary outcomes,
assessed with a 100 mm visual analogue scale. Medication was
stopped In seven patients of the diclophenac plus indomethacine
group after serious gastrointestinal adverse effects.
Risk of bias in included studies
We summarized the quality of the included trials in Table 1. With
respect to selection bias, only one study had both adequate ran-
domization and adequate allocation concealment (Man 2007).
The risk of attrition bias (degree of drop-out and selective drop-
out) was low in one study (Siegel 1994). An adequate intention-to-
treat analysis was only performed in one study (Man 2007). Blind-
ing (performance bias) was adequate in one study (Man 2007).
The other studies were not blinded. Outcome assessment in all
studies was not blinded or no information was provided. The over-
all quality scored according to the three-point scale recommended
in the Cochrane Handbook for Systematic Reviews of Interven-
tions was B (moderate risk of bias) for one study (Man 2007) and
C (high risk of bias) for the two other studies.
Effects of interventions
Efficacy
The efficacy of the three included studies (involving 148 patients)
are summarised in Table 2. From the included studies we extracted
six different outcome measures which represented treatment ef-
ficacy, and provided enough data to analyze them. It should be
noted that if systemic corticosteroids are more effective than the
comparative drugs the presented mean difference is positive.
The average number of days until complete resolution of symptoms
Themeandifferences in the average number of days until complete
resolution of symptoms, between triamcinolone acetonide and
indomethacine, and triamcinolone acetonide andACTHwere 0.9,
and 0.3 days respectively (P-values 0.66, and 0.89; measures of
uncertainty, for example 95% CI, were not reported).
Clinical joint status at three follow-up moments
On comparing triamcinolone acetonide and indomethacine, the
differences between the mean clinical joint scores after 1 to 2, 3
to 4, and 10 to 14 days respectively, as assessed by an unblinded
investigator, were 0.5, 0.03, and -0.3 on a 5-point categorical scale
(P-values 0.24, 0.94, and 0.25 respectively; measures of uncer-
tainty, for example 95% CI, were not reported).
Reduction of the pain at rest per hour during the first two hours
Regarding pain reduction during the first two hours after the start
of the treatment, as assessed by the patient on a VAS of 100 mm,
the mean difference between prednisolone and diclophenac plus
indomethacine was 3.2 mm per hour for pain at rest (95% CI -
0.78 to 7.14).
Reduction of the pain with activity per hour during the first two hours
The mean difference between prednisolone and diclophenac plus
indomethacine was -1.1 mm for the reduction of pain during
activity (95% CI -5.34 to 3.24).
Reduction of the pain at rest per day after two weeks
Regarding the decrease of the pain at rest during the first twoweeks,
the mean difference was 0.5 mm per day (95% CI 0.03 to 0.89)
comparing prednisolone and diclophenac plus indomethacine.
Reduction of the pain with activity per day after two weeks
For the reduction of the pain with activity after two weeks, the
mean difference was 1.2 mm (95% CI 0.44 to 2.00) comparing
prednisolone and diclophenac plus indomethacine.
We did not perform clinical relevance tables for pain or any other
major outcome as the two triamcinolone acetonide studies did not
provide adequate data for this, and the difference in the pain out-
come at the end of the follow up in the third study was statistically
not significant.
Adverse events
No adverse effects were reported in the triamcinolone acetonide-
treated patients or in the ACTH-treated patients (Alloway 1993;
Siegel 1994). In the indomethacine group of the first trial, 20% of
the patients noted dyspepsia (Alloway 1993). In the third study,
statistically significant differences were found in adverse events be-
tween the prednisolone-treated patients and the diclophenac plus
indomethacine-treated patients: 27% versus 63% for any adverse
event; and 0% versus 15% for serious adverse effects requiring
hospital admission (11% gastrointestinal bleeding) (Man 2007).
Adverse effects in the diclophenac plus indomethacine groupwere:
epigastric pain (30%), other abdominal pain (7%), rash (2%),
dizziness (19%), drowsiness (19%), drymouth (24%), indigestion
(30%), nausea (26 %), vomiting (9%), diarrhoea (7%), gastroin-
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testinal haemorrhage (11%), shortness of breath (2%), and chest
pain (2%); and in the prednisolone group: rash (7%), dizziness
(5%), drowsiness (16%), drymouth (20%), indigestion (9%), and
nausea (9%) (Man 2007).
As there were no clinically important adverse events related to the
studied systemic corticosteroids, we had no reason to compile a
clinical relevance table.
Sensitivity analyses
We did not perform any sensitivity analyses as the number of
studies included in our review was too small.
D I S C U S S I O N
In this systematic review we retrieved three studies, including
74 patients with acute gout , that involved treatment with sys-
temic corticosteroids. There were no placebo-controlled studies.
All were active comparator-controlled trials. None of the studies
reported clinically relevant differences between the systemic cor-
ticosteroids and the comparator drugs. No important safety prob-
lems attributable to the corticosteroids were found. Most adverse
events were related to the comparator drugs, in particular to the
NSAIDs.
Conclusions from the present review about the efficacy, effective-
ness, and safety of systemic corticosteroids in the treatment of
acute gout must be interpreted cautiously, for the following rea-
sons.
1. The use of comparator drugs in controlled trials presupposes
efficacy of the comparator drug. However, there is hardly any
evidence for the efficacy of the comparator drugs that were used.
Although the efficacy of NSAIDs is generally accepted, we were
aware of only one placebo-controlled study showing efficacy of
NSAIDs (Sutaria 2006). We were not aware of evidence for the
efficacy of ACTH and, regarding its effectiveness, we located only
one comparator-controlled study (Axelrod 1988).
2. None of the studies were designed to show equivalence. There-
fore, if study outcomes do not show statistical differences (P >
0.05) this does not designate the existence of equal effectiveness
of the studied drugs regarding these outcomes (Jones 1996).
3. The methodological quality of the included studies is very low;
according to the Cochrane Handbook for Systematic reviews of
Interventions two of the three studies were scored C, indicating
very low quality (Alloway 1993; Siegel 1994). The third study was
scored B (Man 2007), indicating moderate quality.
4. There was a substantial heterogeneity between the included
studies. Different kinds of systemic corticosteroids (triamcinolone
acetonide and prednisolone) administered in different ways (in-
tramuscular and oral) were compared with different kinds of com-
parator drugs (indometacine and ACTH). Studies used different
inclusion criteria (for example, diagnosis with and without iden-
tification of MSU crystals) and different outcome measurements
(for example, days until complete resolution, change on a VAS in
mm).
5. Two of the three studies had no predesigned method for how
to register and analyse adverse effects, and the number of patients
was too small to provide a more definitive conclusion about safety.
However, safety problems from systemic corticosteroids in a short
course of treatment are very unlikely in other medical situations
(Rowe 2001; Gotzsche 2005).
The strength of our review is that we searched all available
databases, included publications without language restriction, and
used independent researchers for inclusion and exclusion (with
good kappa values), as well as for data extraction. A limitation was
that we did not request additional data from the authors of the
excluded or included studies, nor did we request gout experts or
pharmaceutical companies to provide unpublished trials.
In conclusion, the efficacy of systemic corticosteroids in acute gout
and their effectiveness, equivalent to the regularly used drugs (in
particular NSAIDs), require more evidence. Derived from this re-
view, the evidence can be graded as a maximum of Silver accord-
ing to the four-point scale grading system (Platinum, Gold, Silver,
and Bronze) described in the book Evidence-based Rheumatology
(Tugwell 2004), and as recommended by the Cochrane Muscu-
loskeletal Review Group.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on this review, we were not able to define evidence-based
implications for medical practice although we expect that systemic
corticosteroids could have the potential to become a safe treatment
alternative in the management of acute gout.
Implications for research
Despite the potential of corticosteroids in relieving inflammation
in acute gout without important safety problems, the real efficacy
and clinical effectiveness requires more evidence. Therefore, well-
designed, high quality trials are necessary. As placebo-controlled
studies are hardly feasible because of ethical considerations, we
advise randomized double blind equivalence trials with NSAIDs
as comparator drugs, given that they have a generally accepted
efficacy and effectiveness. Future trialists should be aware of pre-
defined design conditions (for example a power calculation based
number of patients, range of equivalence) and the use of compa-
rable outcome measures, for example those recommended by the
OMERACT 7 Special Interest group (Schumacher 2005).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alloway 1993
Methods Active comparator controlled non-randomized trial; non blinded
Participants 27 patients (all men) presenting at a hospital rheumatology department with acute gout, diagnosed after
MSU-crystal identification
Interventions 14 patients received a systematic corticosteroid: triamcinolone acetonide (TCA) 60mg by intramuscular
injection, and if necessary a number of additional injections; 13 controls received oral indomethacine
(IDN) 50mg TID, with the permission to taper their medication after at least 2 days in response to
symptomatic improvement (control therapy). TCA treated patients were given additionally paracetamol
with codeine for analgesia
Outcomes The symptomatic improvement on a 5-point scale, the number of active joints, presence of toxicity, and
presence of rebound arthropathy. The final efficacy outcome was the number of days required for total
resolution of all symptoms, and in addition, the clinical joint status at 3 follow-up moments
Notes No outcome measurement by the patient. 4 patients in the TCA group and 3 in the IDM group were lost
to follow up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Man 2007
Methods Active comparator controlled randomized trial; double blinded
Participants 90 patients presenting at a university hospital emergency department with an acute arthritis clinically
“suggestive of gout”
Interventions 44 patients (male 35) received a systematic corticosteroid: 30mg oral prednisolone daily for 5 days. 46
(male 39) patients received indomethacine (IDM) 50mg TID for 2 days and 25mg TID for 3 days after 1
initial intramuscular injection with 75mg diclofenac (control therapy). In both treatment arms additional
paracetamol 1000mg every 4 hours as required
Outcomes Pain reduction at rest, as with activity, scored on a visual analogue scale of 10cm
Notes 7 patients, all from the IDM group, had to stop the study medication because of adverse effects
Risk of bias
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Man 2007 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Siegel 1994
Methods Active comparator randomized controlled trial; non blinded.
Participants 31 patients (all men) presenting at a hospital rheumatology department with acute gout, diagnosed after
MSU-crystal identification
Interventions 16 patients received a systematic corticosteroid: triamcinolone acetonide 60mg by intramuscular injection.
15 received adrenocorticotropic hormone (ACTH) 40 IU by intramuscular injection (control therapy).
If necessary a number of additional injections was given in both treatment arms
Outcomes Patient’s improvement of pain, mobility, and swelling on a 5-point scale, the number of active joints, the
joint status, side effects, and presence of rebound arthropathy. The final efficacy outcome was the number
of days required for total resolution of all symptoms
Notes One patient allocated to ACTH treatment was not characterized, and lost to follow up. Two patients of
the ACTH group were excluded from the analysis because of insufficient response
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Axelrod 1988 Systematic corticosteroids not studied.
Conaghan 1994 Non-systematic review; no clinical trial.
Groff 1990 Prospective, non-controlled trial.
Werlen 1996 No outcome measurement by the patient. No differentiation between patients with gout and patients with chon-
drocalcinosis
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Characteristics of ongoing studies [ordered by study ID]
ISRCTN14648181
Trial name or title Randomized double-blind trial of prednisone and naproxen in treatment of crystal proven acute gout
Methods
Participants Primary care gout patients diagnosed after the identification of MSU crystals
Interventions Five days, by oral administration, either prednisolon 35mg (= 30mg prednisone) once a day or naproxen at
a dose of 500 mg twice a day. Patients received blind capsules containing active prednisolon and placebo
naproxen, or active naproxen and placebo prednisolon
Outcomes Primary outcomes: Patient assessment of pain in the study joint, indicated on visual analogical scales two
times a day, during 4 days ; Secondary outcomes: 1. Patient’s global disability
2. The walking disability, if the study joint was in the leg or foot
3. Safety and tolerability of prednisone versus naproxen.
Starting date April 1st 2004
Contact information Dr E van de Lisdonk, Department of General Practice and Family Medicine 229, Radboud University
Nijmegen Medical Centre
PO Box 9191, Nijmegen, 6500 HB, The Netherlands, Tel +31 (0)24 36
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Quality of studies
Study Randomi-
sation
Allocation
conceal.
Treatment
blinding
ITT analy-
sis
Total drop-
out
Selective
drop-out
Blind out-
come-assess
Overall
quality
A=adequate
B=
unknown or
inadequate
A=adequate
B=
unknown or
inadequate
A=
adequate B=
blinding but
method un-
clear
C=non-
blinded, in-
adequate, or
unknown
A=
adequate B=
ITT inade-
quate C=un-
clear or no
re-
ported data
on drop-out
or loss to fol-
low up
A<15%
B>/=15% or
unknown
A=differ-
ence in
drop-out
rate in main
groups<10%
B>/=10% or
unknown
A=adequate
B=mention-
ing of blind-
ing but exact
method un-
clear C=non
blinded, in-
adequate or
unknown
A=all quality
criteria met
B=one or
more quality
criteria only
partially met
C=one or
more criteria
not met
Alloway
1993
B B C C B A C C
Man
2007
A A B A A B C B
Siegel
1994
B B C C A A C C
Table 2. Efficacy results of included studies
Study n Outcome Results Note
Alloway 1993 I = 14; C = 13 Average number of days
until complete resolution
I 7.4 (SD 4.55); C 8.3
(SD4.35); Difference 0.9
p=0.66
3 of 10 patients received a
second injection (= I). Lost
to follow up: n=7 (I: n=4;
C: n=3)
Mean joint score after 1 to
2, 3 to 4, and 10 to14 days
(5-point scale: 0=total res-
olution, 1=improvement of
> 50%, 2=improvement of
<50%, 3=no change, 4=
worsening of symptoms)
I: 1.0 (SD 0.72) to 0.62
(SD 0.78) to 0.50 (SD 0 .
16).
C: 1.5 (SD 0.85) to 0.65
(SD 0.63) to 0.20 (SD 0.
37); Differences: 0.5 (p=0.
24), 0.03 (p=0.94), and -0.
30 (p=025)
3 of 10 patients received a
second injection (=I). 7 pa-
tients were lost to follow up
(I: n=4; C: n=3)
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Table 2. Efficacy results of included studies (Continued)
Mann 2007 I = 44; C = 46 Mean decrease (mm on a
VAS) per hour of pain at
rest within the first 2 hours
I -9.5 (SD 10.5); C -6.4
(SD 8.3); Difference 3.2
(95%CI -0.78 to 7.14), p=
0.12
The difference in mean
pain score was at no time
more than 13mm, which
was unlikely to be clinically
relevant according to the
authors
Mean decrease (mm on a
VAS) per hour of pain dur-
ing activity within the first
2 hours
I -19.2 (SD 11.2); C -20.
3 (SD 9.1); Difference -1.1
(95%CI:
-5.34 to 3.24), p=0.63
The difference in mean
pain score was at no time
more than 13mm, which
was unlikely to be clinically
relevant according to the
authors
Mean decrease (mm on a
VAS) per day of pain at rest
after 2 weeks
I -0.7 (SD 1.2); C -0.
3 (SD0.7); Difference 0.5
(95%CI: 0.03 to 0.89), p=
0.04
The difference in mean
pain score was at no time
more than 13mm, which
was unlikely to be clinically
relevant according to the
authors.
Lost to follow up: n=7 (I:
n=0; C: n=7*) * had to stop
the study after adverse ef-
fects
Mean decrease (mm on a
VAS) per day of pain dur-
ing activity after 2 weeks
I -2.9 (SD 2.0); C -1.7
(SD 1.6); Difference 1.2
(95%CI: 0.44 to 2.00). p=
0.0026
The difference in mean
pain score was at no time
more than 13mm, which
was unlikely to be clinically
relevant according to the
authors.
Lost to follow up: n=7 (I:
n=0; C: n=7*) * had to stop
the study after adverse ef-
fects
Siegel 1994 I = 16; C = 15 Average number of days
until complete resolution
I 7.6; 7.9; Difference 0.3
p=0.89
4 of 16 patients required a
second I-injection, 9 of 14
a second C-injection. 3 pa-
tients required a thirdC-in-
jection.
Lost to follow up: n=3 (I:
n=0; C: n=3*) *2 because of
<50% improvement after 3
C-injections
I = Intervention; C = Con-
trol
SD = Standard Deviation
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
#1 Gout
“gout” [mh] OR gout* [tw] OR “Hyperuricemia”[mh] OR toph* [tw] OR arthritis uric* [tw] OR artritis uric* [tw] OR uric acid dis*
[tw]
#2 Corticosteroids
“Glucocorticoids”[mh] OR “Adrenal Cortex Hormones”[mh] OR “Steroids”[mh] OR glucocortic* [tw] OR adrenal Cortex Horm*
[tw] OR prednison* [tw] OR prednisol* [tw] OR cortison* [tw] OR hydrocort* [tw] OR methylprednis* [tw] OR triamcinol* [tw]
OR dexamethas* [tw] OR betamethas* [tw] OR beclomethas* [tw] OR paramethas* [tw] OR dexametas* [tw] OR betametas* [tw]
OR beclometas* [tw] OR parametas* [tw]
#3 Controlled trials
(Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (clinical trial [tw])
OR ((singl*[tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (latin square [tw]) OR
placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies
[mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR
volunteer* [tw]) NOT (animal [mh] NOT human [mh])
Whole search
#1 AND #2 AND #3
Abbreviations: mh: exploded medical subject heading (Medline medical index term); mh:noexp: non-exploded medical subject heading
(MEDLINE medical index term); tw = text word; pt = publication type. The asterisk (*) stands for any character(s).
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